ReviewZhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi2026
[Research advances in mesenchymal stem cell therapy for graft-versus-host disease].
Review in Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Graft-versus-host disease (GVHD) remains a severe complication after allogeneic hematopoietic stem cell transplantation, and effective treatment options remain limited, particularly for patients with steroid-refractory GVHD or failure of multiple lines of therapy. Mesenchymal stem cell (MSC) therapy has shown promise for the prevention and treatment of GVHD because of the low immunogenicity and immunomodulatory, anti-inflammatory, and tissue-reparative properties of MSC. To date, MSC-based products have been approved for the treatment of acute GVHD (aGVHD) in several countries, including China. Although MSC therapy is generally well tolerated, its broader clinical application remains challenged by substantial interindividual variability in therapeutic response, potential safety concerns, and the lack of harmonized standards for manufacturing and quality control. This review systematically summarizes recent clinical research on MSC-based interventions for GVHD and critically discusses their therapeutic prospects and current limitations, with the aim of informing standardized and precision-oriented clinical application of MSC therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.